Here is a summary of the content in 400 words:
Immuneel Therapeutics, a leading cell and gene therapy start-up, has unveiled Qartemi, India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL). This milestone marks a significant step forward in India’s cancer treatment landscape, offering personalized therapy for patients with relapsed or refractory B-NHL.
Qartemi is a locally manufactured therapy in Immuneel’s state-of-the-art facility in Bangalore, ensuring global standards of safety and efficacy. The therapy is designed to harness a patient’s immune cells to target and eliminate cancer, offering new hope to those battling aggressive blood cancers.
Immuneel has partnered with top hospitals, including Narayana Health, Apollo Hospitals, CMC Vellore, and others, to provide Qartemi to their patients. The company’s goal is to offer advanced treatments and cutting-edge therapies at an affordable cost, making them accessible to a wider population.
The IMAGINE trial, conducted across several hospitals, showed that Qartemi’s efficacy and safety are similar to CAR T-cell therapies approved by the USFDA, with an 83.3% ORR at Day+90. This milestone has set a new benchmark for CAR-T therapy in India.
Immuneel’s co-founders, Kiran Mazumdar-Shaw and Siddhartha Mukherjee, emphasized the company’s mission to offer affordable and innovative, lifesaving therapies for cancer. They believe that Qartemi’s launch marks a pivotal moment in India’s fight against cancer and redefines what is possible in precision medicine.
The launch of Qartemi is a significant step forward in immuno-oncology, offering a new era of personalized precision therapy. With Qartemi, Indian patients can now access advanced treatment options for relapsed or refractory B-NHL, transforming the therapeutic landscape for blood cancers in India.